Diagnostic Platform Expands to Asthma and COPD Testing
New diagnostic technology, currently covered by insurance, aims to support patients with chronic lung conditions.
Updated on Oct. 27, 2026 in Asthma
Live Poll
Do you trust the accuracy of noninvasive, home-collected diagnostic tests for detecting lung conditions?
In the second quarter of 2026, bioAffinity Technologies reported 200% year-over-year revenue growth for its noninvasive diagnostic platform. The company is now working to expand this testing technology, which analyzes patient-collected sputum samples, to address chronic obstructive pulmonary disease (COPD) and asthma.
Why it matters
The adoption of this diagnostic approach is supported by established reimbursement from Medicare and various private insurers. This coverage framework provides a pathway for patients and providers to utilize new, noninvasive testing methods for chronic lung conditions.
The diagnostic platform, currently supported by Medicare and private insurance coverage, reported 200% year-over-year revenue growth in Q2 2026. The clinical efficacy and diagnostic accuracy of the planned asthma and COPD applications remain under investigation.
The players
bioAffinity Technologies
A developer of noninvasive diagnostic platforms focused on lung health and the analysis of the lung microenvironment.
Pictor
A technology partner collaborating on molecular and proteomic analysis capabilities for diagnostic testing.
AB Medical
A collaborative partner providing support for the deployment of diagnostic technologies.
The details
The platform analyzes the lung microenvironment by evaluating patient-collected sputum samples. These samples are processed using flow cytometry paired with an artificial intelligence-based algorithm to detect cellular changes. Future efforts aim to integrate molecular and proteomic analysis capabilities through a collaboration with Pictor.
Timeline
In Q2 2026, bioAffinity Technologies reported 200% year-over-year revenue growth.
The company also recorded year-over-year revenue growth during the third quarter of 2026.
Health Landscape
The expansion of diagnostic technology into asthma and COPD follows the established pattern of Medicare and private reimbursement supporting new, noninvasive testing methods. This shift reflects a broader trend toward leveraging artificial intelligence and flow cytometry in respiratory diagnostics.
Patients with chronic respiratory symptoms should consult their physician regarding appropriate diagnostic tests currently covered by their insurance. Understanding which noninvasive options are available can help streamline the evaluation of lung health.
The takeaway
As noninvasive diagnostic technology for lung health continues to evolve, staying informed about covered testing options is important. Discuss any new, noninvasive diagnostic tools or monitoring methods relevant to your respiratory health with your primary care physician.
Further reading
Learn more about the latest innovations in Asthma care and diagnostic trends.
Source note: This article includes information reported by Proactiveinvestors NA.
Live Poll
Do you trust the accuracy of noninvasive, home-collected diagnostic tests for detecting lung conditions?
